Myriad Genetics (0K3W) Stock Statistics & Valuation Metrics
Total Valuation
Myriad Genetics has a market cap or net worth of $607.38M. The enterprise value is $636.61M.
- Market Cap
- $607.38M
- Enterprise Value
- $636.61M
Share Statistics
Myriad Genetics has 95,649,640 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 95,649,640
- Owned by Insiders
- 5.82%
- Owned by Institutions
- 1.16%
Financial Efficiency
Myriad Genetics’s return on equity (ROE) is -0.99 and return on invested capital (ROIC) is -10.83%.
- Return on Equity (ROE)
- -0.99
- Return on Assets (ROA)
- -0.52
- Return on Invested Capital (ROIC)
- -10.83%
- Return on Capital Employed (ROCE)
- -0.12
- Revenue Per Employee
- 305.37K
- Profits Per Employee
- -135.52K
- Employee Count
- 2,700
- Asset Turnover
- 1.17
- Inventory Turnover
- 8.10
Valuation Ratios
The current PE Ratio of Myriad Genetics is -5.32. Myriad Genetics’s PEG ratio is -0.08.
- PE Ratio
- -5.32
- PS Ratio
- 0.75
- PB Ratio
- 1.98
- Price to FCF
- -70.62
- Price to Operating Cash Flow
- 78.18
- PEG Ratio
- -0.08
Income Statement
In the last 12 months, Myriad Genetics had revenue of 824.50M and earned -365.90M in profits. Earnings per share was -3.96.
- Revenue
- 824.50M
- Gross Profit
- 576.60M
- Operating Income
- -67.80M
- Pretax Income
- -395.10M
- Net Income
- -365.90M
- EBITDA
- -330.90M
- Earnings Per Share (EPS)
- -3.96
Cash Flow
In the last 12 months, operating cash flow was 7.70M and capital expenditures -16.30M, giving a free cash flow of -8.60M billion.
- Operating Cash Flow
- 7.70M
- Free Cash Flow
- -8.60M
- Free Cash Flow per Share
- -0.09
Dividends & Yields
Myriad Genetics pays an annual dividend of $0.29, resulting in a dividend yield of ―
- Dividend Per Share
- $0.29
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -1.42%
- Earnings Yield
- -18.70%
Stock Price Statistics
- Beta
- -0.01
- 52-Week Price Change
- -19.80%
- 50-Day Moving Average
- 4.14
- 200-Day Moving Average
- 4.56
- Relative Strength Index (RSI)
- 70.68
- Average Volume (3m)
- 10.58K
Important Dates
Myriad Genetics upcoming earnings date is Nov 04, 2026, After Close (Not Confirmed).
- Last Earnings Date
- Jul 30, 2026
- Next Earnings Date
- Nov 04, 2026
- Ex-Dividend Date
- Mar 15, 2022
Financial Position
Myriad Genetics as a current ratio of 2.49, with Debt / Equity ratio of 57.01%
- Current Ratio
- 2.49
- Quick Ratio
- 2.26
- Debt to Market Cap
- 0.21
- Net Debt to EBITDA
- -0.18
- Interest Coverage Ratio
- -6.46
Taxes
In the past 12 months, Myriad Genetics has paid -29.20M in taxes.
- Income Tax
- -29.20M
- Effective Tax Rate
- 0.07
Enterprise Valuation
Myriad Genetics EV to EBITDA ratio is -15.55, with an EV/FCF ratio of -81.71.
- EV to Sales
- 0.87
- EV to EBITDA
- -15.55
- EV to Free Cash Flow
- -81.71
- EV to Operating Cash Flow
- 91.26
Balance Sheet
Myriad Genetics has $115.20M in cash and marketable securities with $210.50M in debt, giving a net cash position of -$95.30M billion.
- Cash & Marketable Securities
- $115.20M
- Total Debt
- $210.50M
- Net Cash
- -$95.30M
- Net Cash Per Share
- -$1.00
- Tangible Book Value Per Share
- $1.24
Margins
Gross margin is 68.83%, with operating margin of -12.22%, and net profit margin of -13.96%.
- Gross Margin
- 68.83%
- Operating Margin
- -12.22%
- Pretax Margin
- -13.86%
- Net Profit Margin
- -13.96%
- EBITDA Margin
- -5.60%
- EBIT Margin
- -11.83%
Analyst Forecast
The average price target for Myriad Genetics is $3.83, which is 11.43% higher than the current price. The consensus rating is Neutral
- Price Target
- $3.83
- Price Target Upside
- 39.23% Downside
- Analyst Consensus
- Neutral
- Analyst Count
- 8
- Revenue Growth Forecast
- -3.16%
- EPS Growth Forecast
- 72.02%
Scores
- Smart Score
- 4
- AI Score
- ―